PMID- 29755994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220317
IS  - 2319-9644 (Print)
IS  - 2279-042X (Electronic)
IS  - 2279-042X (Linking)
VI  - 7
IP  - 1
DP  - 2018 Jan-Mar
TI  - Therapeutic Effects of Low-dose Bismuth Subcitrate on Symptoms and Health-related 
      Quality of Life in Adult Patients with Irritable Bowel Syndrome: A Clinical 
      Trial.
PG  - 13-21
LID - 10.4103/jrpp.JRPP_17_56 [doi]
AB  - OBJECTIVE: Irritable bowel syndrome (IBS) is a chronic functional disorder of the 
      gastrointestinal tract that causes abdominal pain or discomfort and alters bowel 
      with no organic abnormalities. Treatment options for IBS have increased in number 
      in the past decade, and clinicians should not be limited to use only conventional 
      treatments to cure it. This article is a placebo-controlled clinical trial to 
      assess the therapeutic effects of low-dose bismuth subcitrate on symptoms and the 
      health-related quality of life in adult patients with IBS. METHODS: This clinical 
      trial was done during July 2015 to January 2016 in Isfahan, Iran. For each of 
      three subtypes (IBS-constipation dominant, IBS-diarrhea dominant [IBS-D], and 
      IBS-mixed), we included patients with IBS aged 18-70 years, diagnosed according 
      to the Rome III criteria. In this study, 129 eligible patients were enrolled, of 
      which 119 continued on the protocol to the end of study. They were allocated in 
      placebo group (Group A) and intervention group (Group B). The medication for 
      Group B was mebeverine and bismuth subcitrate and for Group A was mebeverine and 
      placebo of bismuth subcitrate. Initially, the patients of both groups completed 
      IBS-related questionnaires (IBS-quality of life, IBS-severity scoring system), 
      then given drugs for a 4-week period (1(st) on-drug period). Then, both groups 
      were given only mebeverine hydrochloride 200 mg capsule for another 4 weeks 
      (off-drug period). At last, Group A and Group B were given medication (2(nd) 
      on-drug period), the same as 1(st) on-drug period. FINDINGS: With respect to 
      quality of life, the trend of IBS-QOL score changed significantly during the 
      study period in both the intervention and placebo groups; however, no significant 
      differences were observed between the two groups (P < 0.005). In subgroups 
      analysis, quality of life significantly improved in IBS-D during the study from 
      the first measurement to the end of study (P = 0.004). The trends of changes in 
      the severity of pain during the study between the intervention and control group 
      were significantly different (P = 0.018). CONCLUSION: According to our study, 
      IBS-D patients' symptoms improved significantly with bismuth therapy. We found 
      that adding low-dose bismuth to mebeverine in nonresponsive IBS patients in 
      conventional treatment could be helpful.
FAU - Daghaghzadeh, Hamed
AU  - Daghaghzadeh H
AD  - Integrative Functional Gastroenterology Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran.
FAU - Memar, Ardalan
AU  - Memar A
AD  - Students' Research Committee, Medical Faculty, Islamic Azad University, Najafabad 
      Branch, Isfahan, Iran.
FAU - Mohamadi, Yasaman
AU  - Mohamadi Y
AD  - Students' Research Committee, Medical Faculty, Islamic Azad University, Najafabad 
      Branch, Isfahan, Iran.
FAU - Rezakhani, Nooshin
AU  - Rezakhani N
AD  - Students' Research Committee, Medical Faculty, Islamic Azad University, Najafabad 
      Branch, Isfahan, Iran.
FAU - Safazadeh, Parastoo
AU  - Safazadeh P
AD  - Students' Research Committee, Medical Faculty, Islamic Azad University, Najafabad 
      Branch, Isfahan, Iran.
FAU - Aghaha, Sarina
AU  - Aghaha S
AD  - Students' Research Committee, Medical Faculty, Islamic Azad University, Najafabad 
      Branch, Isfahan, Iran.
FAU - Adibi, Payman
AU  - Adibi P
AD  - Integrative Functional Gastroenterology Research Center, Isfahan University of 
      Medical Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Res Pharm Pract
JT  - Journal of research in pharmacy practice
JID - 101614023
PMC - PMC5934982
OTO - NOTNLM
OT  - Abdominal pain
OT  - Bismuth subcitrate
OT  - Mebeverine
OT  - bloating
OT  - constipation
OT  - diarrhea
OT  - irritable bowel syndrome
COIS- There are no conflicts of interest.
EDAT- 2018/05/15 06:00
MHDA- 2018/05/15 06:01
PMCR- 2018/01/01
CRDT- 2018/05/15 06:00
PHST- 2018/05/15 06:00 [entrez]
PHST- 2018/05/15 06:00 [pubmed]
PHST- 2018/05/15 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - JRPP-7-13 [pii]
AID - 10.4103/jrpp.JRPP_17_56 [doi]
PST - ppublish
SO  - J Res Pharm Pract. 2018 Jan-Mar;7(1):13-21. doi: 10.4103/jrpp.JRPP_17_56.